Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Diffuse Intrinsic Pontine Glioma: early-phase trial registry
3 of 6 indexed Recurrent Diffuse Intrinsic Pontine Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,876 of 28,963 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,876 of 28,963 conditions by registered trial count
Recurrent Diffuse Intrinsic Pontine Glioma: 6 US clinical trials tracked, 3 recruiting.
Recurrent Diffuse Intrinsic Pontine Glioma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Open enrollment, early-phase tilt
Recurrent Diffuse Intrinsic Pontine Glioma has 6 registered US clinical trials, 3 of them open to new participants right now, about 50% of the total.
- 3
- recruiting participants now
- 50%
- of trials open to enrollment
- 0
- in Phase 3-4 (later-stage)
- 2
- top sponsor: National Cancer Institute (NCI)
Corpus placement: #2,876 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Recurrent Diffuse Intrinsic Pontine Glioma on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Diffuse Intrinsic Pontine Glioma is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 28,061 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Diffuse Intrinsic Pontine Glioma research.
National Cancer Institute (NCI) accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Diffuse Intrinsic Pontine Glioma trials plan to enrol fewer than 100 people.
Median target enrolment is 65 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Recurrent Diffuse Intrinsic Pontine Glioma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of California, San Francisco
NCT05009992
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
NCT05278208
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
NCT04870944
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
NCT02359565
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
National Cancer Institute (NCI)
NCT03598244
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Pediatric Brain Tumor Consortium
NCT03387020
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Recurrent Diffuse Intrinsic Pontine Glioma right now
3 recruiting of 6 indexed (50% open).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top sponsor: National Cancer Institute (NCI) (2 trials), 4 others listed. 6 shown below, recruiting first. #2,876 of 28,963 conditions by registered trial count.
Why a small condition index still matters
Thin indexes still surface the registry rows that exist for this label. Counts stay small when ClinicalTrials.gov lists few studies under the condition string, not because this page omits rows. Verify any enrollment decision on ClinicalTrials.gov and with a clinician.
Frequently Asked Questions
How many clinical trials are there for Recurrent Diffuse Intrinsic Pontine Glioma?
PlainTrial tracks 6 US clinical trials for Recurrent Diffuse Intrinsic Pontine Glioma, of which 3 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Recurrent Diffuse Intrinsic Pontine Glioma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.